[Previous Months][Date Index][Thread Index][Join - Register][Login]   Help@Insulin-Pumpers.org
  [Message Prev][Message Next][Thread Prev][Thread Next]   for subscribe/unsubscribe assistance

Re: [IPp] Omnipid + Dexcom

    They may still.  This agreement is nonexclusive.
Hmmmm... I thought Animas was going to link up with Dexcom....


Insulet's OmniPod(R) Personal Diabetes Manager To Integrate DexCom
Continuous Glucose Monitoring Technology

Insulet Corporation (NASDAQ: PODD), the leader in wearable insulin pump
technology with its OmniPod(R) Insulin Management System, and DexCom, Inc.
(NASDAQ: DXCM), a leading provider of continuous glucose monitoring systems
for people with diabetes, announced they have signed a development agreement
to integrate DexCom's continuous glucose monitoring technology into the
wireless, handheld OmniPod System Personal Diabetes Manager (PDM). In
addition to programming the patient's insulin delivery, the PDM with
integrated DexCom technology will receive and display continuous glucose
readings from DexCom's wearable sensor transmitter. Patients using the
integrated system will have access to real-time glucose values and trended
glucose information, as well as alarms to warn patients if glucose levels
are rising or falling.

"Insulet is a leader in diabetes technology. This development agreement with
DexCom is another example of Insulet's commitment to improving the lives of
people with diabetes through innovation," said Duane DeSisto, president and
chief executive officer of Insulet Corporation. "Integrating DexCom's
technology into the OmniPod PDM will combine the proven benefits of insulin
pump therapy and continuous glucose monitoring in a single safe, discreet
and easy-to-use system."

Terrance H. Gregg, president and chief executive officer of DexCom added,
"We are pleased to work with Insulet Corporation to bring these two
leading-edge technologies together to help people living with diabetes
better manage their disease."

The PDM with DexCom technology will combine the functionality of both
systems' handheld receivers into one single handheld wireless device,
eliminating the need for a separate receiver. The PDM will be used to
program the wearable OmniPod with insulin delivery instructions and will
also receive and display continuous glucose readings directly from DexCom's
wearable sensor transmitter. The integrated system will provide patients
with continuous information about glucose levels and allow patients to
continuously track trends, enabling them to accurately anticipate excursions
outside of normal glucose levels and to make appropriate treatment
adjustments. Alarms on the PDM will immediately alert the patient when
glucose levels are outside of the target range, allowing the patient the
opportunity to intervene and prevent acute events. Development, clinical and
regulatory efforts are expected to continue throughout 2008, with an
anticipated product launch in mid-2009.

The PDM with integrated DexCom technology will broaden Insulet Corporation's
portfolio of diabetes management products. The development agreement between
Insulet and DexCom also contemplates further work by Insulet and DexCom
towards development of a closed-loop system.

The agreement is non-exclusive and does not impact any of Insulet's existing
third party development agreements.


Though no one can go back and make a brand new start, anyone can start from
now and make a brand new ending.
- Carl Bard
for HELP or to subscribe/unsubscribe/change list versions,
contact: HELP@insulin-pumpers.org